Press Release: Positive topline Phase 2b data in atopic dermatitis support amlitelimab as a potential first and best-in-class novel investigational anti-OX40-ligand monoclonal antibody

https://ift.tt/AngCuzI

from Sanofi - Aventis Groupe https://ift.tt/EwXy2d8
via IFTTT